Envestnet Asset Management
RNAM

Envestnet Asset Management’s Avidity Biosciences RNAM Stock Holding History

Envestnet Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,000
Closed -$433K – 4802
2025
Q4 		$433K Sell
6,000
-173,103
-97% -$11.2M ﹤0.01% 3802
2025
Q3 		$7.8M Buy
179,103
+113,545
+173% +$4.59M ﹤0.01% 1930
2025
Q2 		$1.86M Sell
65,558
-3,707
-5% -$110K ﹤0.01% 2874
2025
Q1 		$2.04M Buy
69,265
+36,133
+109% +$1.13M ﹤0.01% 2715
2024
Q4 		$963K Sell
33,132
-3,931
-11% -$164K ﹤0.01% 3197
2024
Q3 		$1.7M Buy
+37,063
New +$1.61M ﹤0.01% 2770

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Envestnet Asset Management's RNAM Position: Q1 2026 in Review

Envestnet Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,000 shares — an estimated $433K sold.

Envestnet Asset Management first reported a position in RNAM in Q3 2024 and held it in 6 quarters. The position peaked at $7.8M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Envestnet Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 6,000 Avidity Biosciences shares in Q1 2026, an estimated $433K.
  • Envestnet Asset Management first reported a position in Avidity Biosciences in Q3 2024 and held it in 6 quarters.
  • Envestnet Asset Management's Avidity Biosciences position peaked at $7.8M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.